AC
RXRX icon

AXQ Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

AXQ Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,960
Closed -$82.2K – 585
2024
Q2 		$82.2K Sell
10,960
-1,840
-14% -$16K 0.02% 419
2024
Q1 		$128K Sell
12,800
-30,400
-70% -$339K 0.03% 563
2023
Q4 		$426K Buy
43,200
+14,200
+49% +$101K 0.11% 300
2023
Q3 		$222K Buy
+29,000
New +$289K 0.08% 363
2023
Q2 		– Sell
-15,374
Closed -$103K – 523
2023
Q1 		$103K Buy
+15,374
New +$122K 0.04% 444

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AXQ Capital's RXRX Position: Q3 2024 in Review

AXQ Capital sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 10,960 shares — an estimated $82.2K sold.

AXQ Capital first reported a position in RXRX in Q1 2023 and held it in 5 quarters. The position peaked at $426K in Q4 2023. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • AXQ Capital reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AXQ Capital sold 10,960 Recursion Pharmaceuticals shares in Q3 2024, an estimated $82.2K.
  • AXQ Capital first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • AXQ Capital's Recursion Pharmaceuticals position peaked at $426K in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on AXQ Capital's 13F filing for Q3 2024, filed 14 Nov 2024.